Library

Place of publication:
therapy, No. 5 (39), 2020

Summary:
in the presented review, the pathogenesis of the coronavirus disease 2019 (Covid-19), features of the SARS-COV-2 virus are considered in detail. Given the great importance in the development of this infection of oxidative stress and hypoxia, it is advisable to use antioxidants and antihypoxants in the complex treatment of Covid-19, which may be useful and significantly improve the course of the disease. Key words : Covid-19, coronaviruses, oxidative stress, hypoxia.

Place of publication:
Journal of Neurology and Psychiatry, 5, 2018

Summary:
Purpose of the study. To study the influence of the original domestic drug Mexidol on the expression of the transcription factor NRF2 in the cores of the cells of the frontal cerebral cortex with one -way occlusion of the general carotid artery. Material and methods. The work was done on 64 sexually mature rats of the Vistar line. The expression of NRF2 was determined by the immunohymic method. Results and conclusion. A single intra -Brushyne administration of Mexidol per 1 kg of body weight of the animal and its course oral administration per 1 kg of mass 3 times a day for 14 days did not affect the expression of the NRF2 factor. Unilateral occlusion of the general carotid artery increased the expression of NRF2 after 4 hours and on the 5th day after modeling occlusion. The oral administration of 100 mg of Mexidol per 1 kg of mass 3 times a day for 14 days before and after modeling ischemia increased the expression of NRF2 after 4 hours and on the 12th day compared to the norm indicators, as well as after 4 hours and on the 12th A day compared with the values ​​of the control of occlusion. Thus, it was established that Mexidol increases the expression of NRF2 in the frontal cortex of the rats of rats not in normal conditions, but with unilateral occlusion of the general carotid artery. Keywords: Mexidol, NRF2, ethylmethylhydroxypyridine succinate, ischemia, occlusion of the general carotid artery.

Place of publication:
Journal of Neurology and Psychiatry, 10, 2017

Summary:
Purpose of the study. To study the influence of Mexidol (ethylmethylhydroxypyridine of succinate) on the expression of the factor induced by hypoxia (HIF-1α), in the bark of the frontal lobe of the large hemispheres of the brain during its ischemia. Material and methods . The work was done on 64 sexually mature rats of the Vistar line. The expression of HIF-1α was determined immunohymic chemically. Results and discussion. It was established that a single intra-Brush administration of Mexidol at a dose of 120 mg/kg of mass and its course oral administration at a dose of 100 mg/kg of mass 3 times a day for 14 days does not affect the expression of the HIF-1α factor. Unilateral occlusion of the general carotid artery increases the expression of HIF-1α after 4 hours from the moment of occlusion. The oral introduction of Mexidol at a dose of 100 mg/kg of mass 3 times a day for 14 days before and after ischemia, increases the expression of HIF-1α after 4 and 12 hours compared with the norms of the norm on the 5th day compared to the values ​​of occlusion control. Thus, it was established that Mexidol increases the expression of HIF-1α in the frontal cortex of the rats of rats not in normal conditions, but with unilateral occlusion of the general carotid artery.

Place of publication:
neurology, neuropsychiatry, psychosomatics, 2017, No. 9

Summary:
The purpose of the study is a comprehensive assessment by means of pharmacinformation profiling of all possible effects of mexidol molecules, alfoseta choline, piracetam, glycine, semax in accordance with anatomical and therapy-chemical classification. Material and methods. Hemoreactomic, pharmacinformation and geronto -informational analyzes of the properties of molecules are based on a chemorectic methodology. For chemoreactic analysis, information from the databases Pubchem, HMDB and String was used; For pharmacinformation analysis - information from the international classification of ATX and a combined data selection from the TTD (Therapeutic Target Database), Supertarget, Matador (Manually Annoted Targets and Drugs Online Resource) and PDTD (Potential Drugs Database); For gerontoinformation analysis, data on the heroroprotective action of individual substances from the Pubchem database and the literature on Heroproteus from the Pubmed base, collected through the system of artificial intelligence. Results and discussion. Mexidol is characterized by a maximum set of positive effects (a drug for the treatment of central nervous system diseases, cardiovascular pathology, metabolic disorders, which has anti-inflammatory and anti-infectious properties, etc.). Mexidol and glycine predict the smallest frequencies of such side effects as itching, constipation, paresthesia, vomiting, etc. Geronto -information assessments of changes in the life expectancy of model organisms showed that Mexidol helps to increase the average life expectancy of C. Elegans (by 22.7 ± 10%) , Drosophiles (by 14.4 ± 15%) and mice (by 14.6 ± 3%, control drugs - not more than 6.1%). Conclusion. The results of the study indicate the high potential of Mexidol for use as a hero of the Heroprotector.

Place of publication:
a journal of neurology and psychiatry, 1, 2017; Ext. 2

Summary:
Purpose of the study. Comparative chemorectic analysis of the Mexidol molecule (ethylmethylhydroxypyridine succinate) with control molecules (alpha alphascerate, piracetam, glycine, semax). Material and methods . Comparisons of the chemical structure of Mexidol with molecules in the database of human metabolism and molecules in the databases of drugs. More than 40,000 compounds given in the HMDB (Human Metabolome Database) were used as a human metabolism. Results and conclusion. Hemorestom analysis showed that Mexidol can be an agonist of acetylcholine and gamut-a receptors; anti -inflammatory agent, the effects of which occur due to inhibiting the synthesis of pro -inflammatory prostaglandins; neuroprotective agent with neurotrophic properties; coagulation inhibitor; sugar -lowering and hyalipidemic agents. Mexol molecules are distinguished by a more pronounced safety profile (less impact on serotonin, dopamine and adrenergic receptors, a lower degree of interaction with potassium potatoes, Mao enzymes and p450 cytochromas). The results of modeling allow at the molecular level to clarify the mechanism of action of the Mexidol molecule.

Place of publication:
Journal of Neurology and Psychiatry, 8, 2014

Summary:
The purpose of the study is to study the penetration of Mexidol through the hematoencephalic barrier (GEB) in different parts of the brain and mitochondria of cells. Material and methods. Used the drug Mexol LLC NPK Pharmasoft (Russia). They studied the penetration of large hemispheres, cerebellum, thalamus and oblong brain into the fabric and the distribution between mitochondrial and cytoplasmic fractions of nerve cells. The concentration of Mexidol in the blood plasma and brain tissue was analyzed by the method of highly effective liquid chromatography. Results and conclusion. It was established that Mexidol penetrates through the GEB into different parts of the brain of rats. Its greatest concentration is determined in the fabric of the bark of large hemispheres. Inside the nerve cells of Mexidol is found both in the cytoplasmic and mitochondrial fractions. Keywords: Mexidol, Pharmacokinetics, Hematoencephalic Barrier, Big Hses, Mozheschok, Thalamus, Minuted Brain, Mitochondria, Highly Effective Liquid Chromatography.

Place of publication:
Bulletin of experimental biology and medicine, 2006, Appendix 1

Summary:
the influence of Mexidol in different doses in the dynamics of the development of experimental toxic hepatitis according to indicators of hydration and free radical oxidation in the blood and liver tissue has been studied. A positive and dose-dependent effect of Mexidol on the studied physicochemical processes in the blood and liver tissue in the experiment is established, its use in patients with diffusion liver diseases is theoretically substantiated. Key words: hepatology, intoxication, free radical processes, Mexidol.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, No. 4, 2019

Summary:
the review presents data on the combined use of Mexidol in combination with drugs of various pharmacotherapeutic groups. Possessing the multimodal action mechanism and a wide range of pharmacological effects, Mexoling enhances the main effect of drugs both in the experiment and in the clinic, increases the effectiveness of therapy prescribed by patients in accordance with current federal standards, and also helps to reduce the severity of complications of diseases. The data on the efficiency and pathogenetic validity of the course combination therapy with other preparations presented in the review indicate the advisability of this approach for the treatment of cerebrovascular and cardiovascular diseases, diseases of the nervous system, open-angle glaucoma, alcohol intoxication and a number of other diseases. Key words: Mexidol, combined therapy, free radicals, lipid oxidation, ischemic stroke, myocardial infarction, coronary heart disease, epilepsy, glaucoma, alcohol intoxication.

Place of publication:
Bulletin of experimental biology and medicine, 2006, Appendix 1

Summary:
on the model of experimentally caused intracerebral post -traumatic hematoma (hemorrhagic stroke), rats have established that the drug Mexidol is effective at a dose of 100 mg/kg (course - 7 days). The drug statistically reliably reduced the number of neurological disorders (paresis, manners), increased animal survival, improved the processes of learning and memory of rats with hemorrhagic stroke, as well as their motor activity. Key words: Mexidol, hemorrhagic stroke, neurological status, memory

Place of publication: Farmatek magazine Special Psychiatry / Neurology / 2016

Mexidol is an original domestic drug. The article describes the history of the creation of the drug, outlines modern ideas about its pharmacokinetics (including data on the penetration of Mexidol into mitochondria, as well as its effect on the activity of cytochroma-R450 isform 3A4 and protein-conveyor glycoprotein-r) and pharmacodynamics. From a biochemical point of view, the appropriateness of the use of Mexidol with hypoxia of the brain, the development of oxidative stress, with glutamate exaytotoxicity is substantiated. The comparison of Mexidol and its generics, as well as studies proving the safety of this drug, are presented.

Keywords: Mexidol, ethylmethylhydroxypirinate, pharmacokinetics, pharmacodynamics, safety

Place of publication:
a journal of neurology and psychiatry, No. 12, 2012

Summary:
Mexidol (2-El-methyl-3-gydro Xipina Ridina Succinate)-a domestic original antioxidant and anti-hyphyxant, created at the Research Institute of Pharmacology of the RAMS in the mid-80s. Mexol consists of two related and functionally significant compounds: 2-ethyl-6-methyl-3-hydroxypyridine and amber acid. The presence of 3-hydroxypyridine in the structure of Mexidol provides a complex of its antioxidant and membranotropic effects, the ability to reduce glutamate excanitotoxicity, modulate the functioning of receptors, which fundamentally distinguishes Mexol from other preparations containing amber acid. The presence of succinate in the structure of Mexidol distinguishes it from Emoxypin and other 3-oxypyridine derivatives, since the succinate is functionally significant for many processes occurring in the body and, in particular, is a substrate for increasing energy metabolism in the cell.

Place of publication:
Pharmacate, No. 6, 2009

Summary:
The article presents viewing data on pharmacological effects and pharmacokinetics of Mexidol. Neuroprotective, anti -hypic, anti -ischemic, nootropic, anti -stress, anxiolytic, anticonvulusal, anti -alcohol, anti -anatherogenic, heroesidal action of Mexidol is considered. Particular attention is paid to the effects of Mexidol in the treatment of diseases occurring with neurodegeneration, primarily acute and chronic disorders of cerebral circulation. Information is presented about the polycomponent mechanism of action of Mexidol, the important links of which are its antioxidant, membrane effects, the ability to modulate the functioning of receptors and membrane -raised enzymes, as well as restore the neurotransmitted balance.

Year of publication: 2004

Summary:
in recent years, close attention of pharmacologists and clinicians as promising drugs that effectively regulate oxidation and peroxidation processes attracted compounds of heteroamatic phenols, in particular, 3-oxypyrin derivatives. 3-oxypyridine derivatives (3-OP) belong to the simplest heterocyclic analogues of aromatic phenols and in this regard show antioxidant and anti-radical properties. They are structural analogues of the compounds of the Vitamin B6 group (pyridoxol, pyridoxal and pyridoxamine), playing an important role in the life of the body. The synthesis and analysis of the physicochemical properties of a number of original derivatives of 3-Op was carried out by L.D. Smirnov, K.M. Dyumaev, V.I. Kuzmin, and their pharmacological study was carried out in the laboratory of psychopharmacology of the Research Institute of Pharmacology of the Russian Academy of Sciences under the guidance of a honored science figure of Professor T.A. Voronina.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2021, T. 121, No. 6

Summary:
the state of cancellation of alcohol develops with the refusal of drinking alcohol, after prolonged or short -lived, but their massive use, is manifested by somatic symptoms and, in some cases, is complicated by the development of alcoholic seizures, alcoholic hallucinosis and alcohol delirium, which can create a threat to patients. The leading neurochemical factors underlying alcohol cancellation and its complications are the insufficient cerebral content of the GABA and the excessive activity of glutamate, which matters to therapy. First -line preparations in the treatment of alcohol and alcoholic delirium cancellation are benzodiazepines with maximum pharmacological similarities with ethanol. As an alternative to benzodiazepines and in addition to them, especially in the case of protracted delirium with therapeutic resistance, other drugs, including barbiturates, antiepileptic drugs, propofols, dexemedetomidine and antipsychoticism, can be used. Certain prospects in the treatment of alcohol cancellation syndrome are associated with ethylmethylhydroxypyridine with a succinate, which has some pharmacological similarity with benzodiazepines. Key words: alcohol disorders, alcohol cancellation syndrome, alcohol convulsions, alcoholic hallucinosis, alcoholic delirium, benzodiazepines.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 5

Summary:
A review of modern literature is presented regarding the use of Mexidol (ethylmethylhydroxypyridine succinate) in the treatment of mental (in particular, addictive) disorders. The possibility of its prescription for the correction of negative psychopathological symptoms, neurocognitive deficiency, manifestations of neuroleptic syndrome (including its extrapyramidal disorders) in the treatment of antipsychotics in patients with schizophrenic spectrum, insomnic disorders in the complex therapy of border mental disorders is shown. The possibilities of the use of the drug Mexidol in the treatment of addictive pathology, as well as the consequences of intoxication caused by alcohol and other psychoactive (in particular, narcotic) substances deserve. Key words: mental disorders, addictive pathology, Mexidol, treatment, complex therapy.

Place of publication:
Journal of Neurology and Psychiatry, 2, 2013

Summary:
70 patients with panic disorder (PR), 30 men and 40 women were examined, whose average age was 34.5 ± 1.8 years. All patients were distinguished by the presence of dissocation disorders. Patients, depending on the characteristics of therapy, were divided into 2 groups - control and basic. Patients of the control group were treated only with an antidepressant (freedin at a dose of 150 mg per day); Mexidol (375 mg per day) was appointed to patients of the main group to antidepressant.